CE Education
Managing AML: Staying on Track in a Rapidly Changing Treatment Landscape
Expiration Date: September 09, 2021
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Actinium Pharmaceuticals, Bristol-Myers Squibb, and Jazz Pharmaceuticals.
Applying Key Data Presented at EHA 2020 to Practice
Expiration Date: December 15, 2021
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol Myers Squibb, Helsinn, Genentech, and Jazz Pharmaceuticals.
Novel Treatment Options in Secondary AML
Expiration Date: December 07, 2021
Today, there are many tools that can be utilized to determine a patient’s diagnosis. In this activity, Dr. Eunice Wang discusses initial diagnosis, disease prognostication, developing a treatment plan for secondary AML including novel treatment options, and incorporating this data into personalized treatment. She will also cover her recommendations for how to manage patients with secondary AML.
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol Myers Squibb, Genentech, Helsinn, and Jazz.
Treatment Advances in Acute Myeloid Leukemia and Myelodysplastic Syndromes
Expiration Date: October 16, 2021
Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) are challenging for healthcare providers to treat and manage, partly because of the complexities surrounding diagnosis and prognosis, and because most patients are older. In this activity, two experts review cytogenetic and molecular abnormalities in AML and MDS, types of testing, and novel targets of treatment. They will also discuss case vignettes that support best practice for patients with AML and MDS.
This activity was previously presented between October 05 and 13, 2020 as a live webinar. Please note: If you participated in one of the live webinars, you are ineligible to receive an additional 1.0 contact hour of credit and may not re-submit for credit previously awarded.
Provided by University of Nebraska Medical Center and MediCom Worldwide, Inc.
This activity is supported by educational grants from Astex Pharmaceuticals and Daiichi Sankyo.
Apoptosis and Selective BCL Inhibition: Changing Treatment Paradigms in AML
Expiration Date: October 01, 2021
The inclusion of BCL2-inhibitor based therapy has revolutionized the treatment of patients with acute myeloid leukemia (AML), particularly for patients who are elderly or unfit for intensive chemotherapy. This approach is now considered standard of care in this setting, which was confirmed by findings from the phase 3 VIALE-A trial. In this article, Marina Konopleva, MD, PhD, reviews the pharmacotherapeutic rationale for selective BCL2 inhibition in AML and the clinical data supporting this treatment approach.
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Helsinn.
New Advances in AML
Expiration Date: July 10, 2021
In order to successfully develop targeted treatment plans and meet the clinical and disease needs of individual patients with acute myeloid leukemia (AML), one must understand the key safety and efficacy data. This activity will focus on practical expert recommendations for optimizing the use of new and recently approved agents and regimens. Hear from three experts as they review the most appropriate therapeutic strategies for individual patients.
This activity was previously presented as a webinar with live Q&A in June and early July of 2020. Please note: If you participated in the live webinar, you are ineligible to receive an additional 1.0 contact hour of credit and may not re-submit for credit previously awarded.
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation, Helsinn, and Pfizer, Inc.
Investigating Maintenance Therapy in AML: Improving Disease-free Survival in Older Patients
Expiration Date: June 29, 2021
The current paradigm of AML treatment involves two phases, intensive induction chemotherapy with the goal of inducing a complete remission, followed by consolidation in hopes to deepen the response and try to eradicate any residual disease that remains. In this interview, we discuss how maintenance therapy may be incorporated into this current treatment paradigm. Read on and review how Dr. Kadia explains how maintenance therapy could shift the paradigm and which patients are likely to benefit. He will describe the role of hypomethylating agents in maintenance therapy and the significance of CC-486, an oral azacitidine, currently in clinical trials.
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Helsinn.
Individualizing Treatment with New and Emerging Targeted Agents in AML
Expiration Date: May 27, 2021
In recent years, AML has been characterized from molecular perspectives and with identifications of recurrent mutations. The standard of care for our older patients with AML is rapidly evolving. There are a number of new combinations and FDA approvals available for use today in our patients. Our increasing understanding of AML biology is leading to further rational drug development and effective targeted agents. In the past three years we have been fortunate to have eight new drugs FDA approved across the spectrum of disease. In today’s presentation, Dr. Jonas will also focus specifically on the mechanism of action and novel targets of BCL-2 and a SMO inhibitor, providing you with an overview of safety and efficacy as reported in clinical trials.
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Helsinn.
The Changing Face of Newly Diagnosed AML: Is There a Role for IDH Inhibitors?
Expiration Date: April 30, 2021
In this activity, Dr. Pollyea will outline the clinical imperative for mutational testing for IDH mutations during prognosis of AML and the implications of IDH1 and IDH2 mutations on prognosis and treatment selection. He will share the latest data which compare and contrast trial endpoints of elimination of minimal residual disease versus mutational clearance and relate each to its clinical impact in newly diagnosed AML patients. In addition, Dr. Pollyea will report on promising clinical trials of IDH1 and IDH2 inhibitors for AML, both alone and in combination with other therapies in the frontline setting.
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Helsinn.
The Role of HDAC Inhibition in the Frontline Setting
Expiration Date: April 22, 2021
In this activity, Dr. Atallah explains the mechanism of action and emerging role of HDAC inhibitors in the treatment of acute myeloid leukemia. In his interview, Dr. Atallah answers questions regarding emerging data and efficacy reported in clinical trials to date, looking at response as a single agent as well as studies evaluating combination therapies with HDAC inhibitors.
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Helsinn.
Transplant as an Option for Patients with AML: Current Standard of Care
Expiration Date: March 12, 2021
In this activity, Dr. Sergio Giralt discusses the role of transplant in light of the new agents that are now available, which patients should be considered for stem cell transplant, and the barriers and challenges that confront patients and their families as they face important treatment decisions.
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Helsinn.
Practical Strategies for Optimizing IDH Inhibitor-based Therapy in Relapsed/Refractory AML
Expiration Date: February 19, 2021
Prognostication in AML has become more challenging as each new treatment regimen receives approval. In this activity, Dr. Amir Fathi discusses the current standard of care for risk stratification in AML and how to incorporate genetic testing results in treatment selection. The goal of this activity is to improve the knowledge and competency of oncology providers in the safety and efficacy of IDH Inhibitors and their role in the treatment of AML.
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Helsinn.
ASH 2019 Annual Meeting Highlights in Acute Myeloid Leukemia
Expiration Date: January 03, 2021
In this activity, you will view video highlights from the 2019 American Society of Hematology (ASH) Annual Meeting. Experts share their insights on a variety of abstracts, covering topics including, but not limited to: IDH2 mutations, quizartinib in patients with relapsed/refractory (R/R) AML, and venetoclax-based therapies in newly-diagnosed and R/R AML.
Chapter 1: Pooled Safety Analysis of Quizartinib Monotherapy in Patients with Relapsed/Refractory AML - Jorge E. Cortes, MD
Chapter 2: Encouraging Clinical Profile of IMG632 and Updated Results from Venetoclax in Combination with Idasanutlin - Naval Daver, MD
Chapter 3: PRIMULA and ASCERTAIN: Updates from Two Potentially Practice-changing Studies - Guillermo Garcia-Manero, MD
Chapter 4: Mutations in Patients with R/R AML Who Received Gilteritinib or in Response to Quizartinib or Salvage Chemotherapy - Alexander Perl, MD
Chapter 5: Relapse Following Ivosidenib Monotherapy in Patients with IDH1 Mutant R/R AML and Enasidenib plus Azacitidine Improves CR and Overall Response Rates in ND AML - Eytan M. Stein, MD
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grant from Celgene Corporation and Helsinn.
Research Report: IDH Inhibitor-based Therapy in AML
Expiration Date: December 13, 2020
The role of IDH1/2 inhibitors are established as treatments for relapsed/refractory (RR) AML, and the IDH1 inhibitor ivosidenib has recently been approved by the FDA for adults aged 75 years or older with newly diagnosed AML who have an IDH1 mutation as detected by an FDA-approved test or are ineligible for intensive induction chemotherapy. In this activity, Dr. Eytan Stein discusses the rationale for studying IDH1/2 inhibitors in both newly diagnosed AML and RR AML, including the clinical implications that come with these approvals.
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Helsinn.
Expanding Therapeutic Options in High-risk AML
Expiration Date: November 22, 2020
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Helsinn.
Evolving Practice in AML: A Case-based Guide to New and Emerging Treatment Options
Expiration Date: October 11, 2020
This activity was previously presented on September 11, 2019 to a live audience during the 2019 SOHO Annual Meeting in Houston, Texas.
Please note: If you attended the live meeting or simulcast viewing, you are ineligible to receive an additional 1.25 contact hours of credit and may not re-submit for credit previously awarded.
Provided by MediCom Worldwide, Inc.
Supported by educational grants from Agios Pharmaceuticals, Inc., Astex Pharmaceuticals, Jazz Pharmaceuticals plc, and Pfizer Inc.
Emerging Approaches to Relapsed/Refractory AML
Expiration Date: February 08, 2020
Strategies for managing patients with relapsed/refractory (R/R) AML continue to evolve as new therapies are introduced into the treatment armamentarium. In this activity, Dr. Alexander Perl describes important considerations and challenges that can impact the care of patients with R/R AML and strategies for determining eligibility for stem cell transplantation. Efficacy and safety data regarding current and emerging pharmacologic treatment options for R/R AML are also reviewed.
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Inc., Celgene Corporation, Daiichi Sankyo, Inc., Helsinn Healthcare SA, and Jazz Pharmaceuticals
New Cytotoxic Agents in Secondary and Treatment-related AML: Practical Strategies for Optimizing Outcomes
Expiration Date: January 09, 2020
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Inc., Celgene Corporation, Daiichi Sankyo, Inc., Helsinn Healthcare SA, and Jazz Pharmaceuticals.
ASH 2018 Annual Meeting Highlights in Acute Myeloid Leukemia
Expiration Date: December 21, 2019
In this activity, view video highlights from the 2018 American Society of Hematology (ASH) Annual Meeting and listen as experts share their insights on a variety of abstracts, covering topics including, but not limited to: the efficacy and safety of emerging drugs for relapsed/refractory AML; venetoclax in combination for older AML patients who are ineligible for intensive chemotherapy; and the status of various clinical trials.
Chapter 1: Improving Outcomes in R/R AML: Can Unique Combinations of Novel Agents Impact Prognosis? Early Trial Results of Venetoclax + Idasanutlin and Azacitidine + Nivolumab, Azacitidine + Ipilimumab
Chapter 2: Maximizing Efficacy Across the Spectrum of AML: Early Clinical Trial Results of the FLT3 Inhibitor Quizartinib in Newly Diagnosed and R/R AML
Chapter 3: The Clinical Challenge of Older AML Patients Ineligible for Intensive Chemotherapy: Clinical Trial Results of Venetoclax in Combination with Cytarabine and HMAs
Chapter 4: The Emerging Role of Bispecific Antibodies in AML: Promising Early Trial Results
Chapter 5: Ivosidenib and Enasidenib: Do These IDH Inhibitors Impact Survival in Newly Diagnosed AML Patients?
Chapter 6: Newer Generation Antibody-Drug Conjugates: Is There a Future For Monotherapy and/or Combination Strategies with Oral Agents in AML?
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Celgene Corporation, Daiichi Sankyo, and Helsinn Healthcare SA, and Jazz Pharmaceuticals.
Novel Therapeutic Approaches in Newly Diagnosed Younger Patients with AML
Expiration Date: November 30, 2019
Treatment options for younger patients with newly diagnosed AML are expanding, with the recent approvals of several targeted therapies, as well as clinical trials investigating novel agents. In this interview, Dr. Pinkal Desai discusses the diagnosis and prognosis of younger people with AML, current standards of care, and key data from clinical trials assessing novel targeted combination therapies to optimize the management of this unique patient population.
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Inc., Celgene Corporation, Daiichi Sankyo, Inc., Helsinn Healthcare SA, and Jazz Pharmaceuticals
Managing High-Risk and Relapsed/Refractory AML: Where Is Research Headed Next?
Expiration Date: November 28, 2019
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Inc., Celgene Corporation, Daiichi Sankyo, Inc., Helsinn Healthcare SA, and Jazz Pharmaceuticals
Editor’s Note: Following the release of this activity, on November 21, 2018 the FDA approved venetoclax in combination with azacitidine or decitabine or low-dose cytarabine for the treatment of newly-diagnosed AML patients who are age 75 years or older, or have comorbidities that preclude use of intensive induction chemotherapy.
Optimizing Treatment in the Older Patient with AML
Expiration Date: November 06, 2019
AML is typically a disease of older adults, a group of patients that fares significantly worse than their younger counterparts. As the treatment landscape for AML continues to expand, clinicians must have a practical, working knowledge of important considerations when managing older patients to individualize therapy. In this activity, Dr. Farhad Ravandi discusses strategies to optimize treatment in older AML patients, describing how age is a factor in AML and outlining emerging approaches to managing this difficult-to-treat patient population.
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Inc., Celgene Corporation, Daiichi Sankyo, Inc., Helsinn Healthcare SA, and Jazz Pharmaceuticals
Editor’s Note: Following the release of this activity, on November 21, 2018 the FDA approved venetoclax in combination with azacitidine or decitabine or low-dose cytarabine for the treatment of newly-diagnosed AML patients who are age 75 years or older, or have comorbidities that preclude use of intensive induction chemotherapy.
The Evolving Standard of Care in AML: FLT3 Inhibitors
Expiration Date: October 16, 2019
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Inc., Celgene Corporation, Daiichi Sankyo, Inc., Helsinn Healthcare SA, and Jazz Pharmaceuticals
Evolving Paradigms in AML: Symposium Replay
Expiration Date: October 12, 2019
Evolving Paradigms in AML: Navigating New Therapeutic Opportunities in the Frontline and Relapsed Settings is a digitally captured archive of a live independent satellite symposium held on September 13 during the SOHO 2018 Meeting. The medical landscape of AML continues to evolve, as evidenced by the approval of five new agents since April 2017 and the anticipated approval of additional novel agents in the very near future. An explosion of clinical trials and updated practice guidelines – coupled with a multitude of therapies in late-stage development – has created the vast challenge of staying up-to-date with clinical evidence impacting practice and patient outcomes. Our experts provide a high-level overview of the latest data from newly diagnosed to relapsed disease, focusing on the most current therapeutic landscape.
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Inc., Daiichi Sankyo, Inc., Helsinn Healthcare SA, and Jazz Pharmaceuticals.
The Expanding Landscape: Promising Novel Agents in Clinical Trials
Expiration Date: September 28, 2019
As the treatment landscape for both newly diagnosed and relapsed/refractory AML continues to expand, clinicians must have a practical, working knowledge of the efficacy and safety data of recently approved therapies beyond FLT3 inhibitors as well as novel agents in clinical development. In this activity, Dr. Daniel Pollyea describes several of the current and emerging therapies that are being investigated in clinical trials as treatment for AML.
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Inc., Celgene Corporation, Daiichi Sankyo, Inc., Helsinn Healthcare SA, and Jazz Pharmaceuticals
EHA 2018 Annual Congress Highlights in Acute Myeloid Leukemia
Expiration Date: August 22, 2019
In this activity, view video highlights from the 2018 European Hematology Association (EHA) Annual Congress and listen as experts share their insights on a variety of abstracts covering topics including, but not limited to: the efficacy and safety of emerging drugs for newly diagnosed and relapsed/refractory AML; monotherapy and combination treatments in clinical trials; and sequencing of therapy for relapsed/refractory disease.
- Chapter 1: Key Findings in AML: An Overview
- Chapter 2: Quizartinib: An Emerging Treatment Option for Relapsed/Refractory FLT3 ITD AML
- Chapter 3: Strategies for Achieving Durable Responses in Elderly AML Patients
- Chapter 4: Enasidenib in Newly Diagnosed and Relapsed/Refractory Mutant IDH2-positive AML
- Chapter 5: Emerging Combinations and Therapies in Newly Diagnosed and Relapsed/Refractory AML
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Inc., Celgene Corporation, Daiichi Sankyo, Inc., and Helsinn Healthcare SA
ASCO 2018 Annual Meeting Highlights in Acute Myeloid Leukemia
Expiration Date: July 31, 2019
In this activity, participants will hear key highlights of several significant scientific updates in acute myeloid leukemia (AML) presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting. Experts will share insights on a variety of abstracts covering topics including: treatment selection strategies, targeted combination therapies, immunotherapies, and novel agents for both newly diagnosed and relapsed/refractory AML patients. Don’t miss this opportunity to see how the future of treatment in AML is evolving, and how these changes may positively impact patient outcomes.
- Chapter 1: Key Findings in AML: An Overview
- Chapter 2: New Data from the Ongoing Phase 1 Study Evaluating Single-Agent IDH1 Inhibitor AG-120 in Relapsed/Refractory AML
- Chapter 3: Two Phase 3 Trials in Progress: HDAC Inhibitor Pracinostat in Combination with Azacitidine; NEDD Inhibitor Pevonedistat + Aza
- Chapter 4: Post hoc Analysis of Clinical Activity of Quizartinib in Patients with Prior TKIs
- Chapter 5: IDH1 and IDH2 Inhibitors in Combination with Aza in the Upfront Setting
- Chapter 6: The Role of Nivolumab in Maintenance Therapy; BCL-2 Inhibitor Studies in Newly Diagnosed AML; Impact of NGS on Therapy Selection
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Inc., Celgene Corporation, Daiichi Sankyo, Inc., and Helsinn Healthcare SA
Are IDH2 Inhibitors Right for Your AML Patient?
Expiration Date: May 15, 2019
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Inc., Celgene Corporation, Daiichi Sankyo, Inc., and Helsinn Healthcare SA.
ASH 2017 Annual Meeting Highlights in Acute Myeloid Leukemia
Expiration Date: December 21, 2018
In this activity, participants will learn about key highlights of the latest and most impactful data in acute myeloid leukemia (AML), presented at the 2017 American Society of Hematology (ASH) Annual Meeting.
Chapter 1: Developments in FLT3 Inhibitors, Chemotherapy, and Small Molecule Inhibitors
Chapter 2: Pracinostat with Azacitidine in Elderly Patients
Chapter 3: CPX-351 vs 7+3 in Older Adults: Efficacy and Safety Reported in Clinical Trial
Chapter 4: Biomarker-driven Treatments: Ivosidenib, Enasidenib, and Sy-1425
Chapter 5: Combination Therapies Involving Gilteritinib and Venetoclax
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Celgene Corporation, Helsinn Healthcare SA, Incyte Corporation, Jazz Pharmaceuticals, Inc., and Novartis Pharmaceuticals.
The Evolving Treatment Landscape in AML
Expiration Date: December 31, 2020
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Celgene Corporation, Helsinn Healthcare SA, Incyte Corporation, Jazz Pharmaceuticals, Inc., and Novartis Pharmaceuticals.
Novel Treatment Combinations in Development for AML: The Role of Hypomethylating Agents
Expiration Date: October 30, 2018
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Celgene Corporation, Helsinn Healthcare SA, Incyte Corporation, Jazz Pharmaceuticals, Inc., and Novartis Pharmaceuticals.
EHA 2017 Congress Highlights in Acute Myeloid Leukemia
Expiration Date: July 21, 2018
In this activity, participants will learn about key highlights of the latest and most impactful data in acute myeloid leukemia (AML), presented at the 2017 European Hematology Association (EHA) 22nd Congress.
Chapter 1: Combination Therapy with Novel Agents and Chemotherapy Improves Survival in Diverse Subsets of AML Patients
Chapter 2: Safety and Efficacy of Enasidenib in Patients with Mutant-IDH2 Relapsed AML
Chapter 3: Improving Efficacy of Mutation-specific Therapeutic Options in AML: Emerging Data and Novel Agents
Chapter 4: Improved Efficacy, Safety with CPX-351 in Older Adults with Newly Diagnosed Therapy Related AML
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Celgene Corporation, Helsinn Healthcare SA, Incyte Corporation, Jazz Pharmaceuticals, Inc., and Novartis Pharmaceuticals.
Tailoring Therapy to Older Patients with Acute Myeloid Leukemia
Expiration Date: September 14, 2018
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Celgene Corporation, Helsinn Healthcare SA, Incyte Corporation, Jazz Pharmaceuticals, Inc., and Novartis Pharmaceuticals.
Breaking New Ground in AML: Practical Applications of Emerging Treatment Options
Expiration Date: July 21, 2018
This activity has been developed from a live symposium held in conjunction with a clinical oncology meeting held in June 2017, focusing on the newest advancements in acute myeloid leukemia (AML). Drawing upon both clinical trial data and analysis of case vignettes, a distinguished faculty panel discusses not only new and emerging strategies in the diagnosis, prognosis, and treatment of AML, but also how these critical new advances will change practice in the near future.
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Inc., Astellas, Celgene Corporation, Helsinn Healthcare SA, Incyte Corporation, and Jazz Pharmaceuticals.
Exploring Epigenetics in AML Oncogenesis
Expiration Date: June 23, 2018
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Inc., Celgene Corporation, Helsinn Healthcare SA, Incyte Corporation, Jazz Pharmaceuticals, Inc., and Novartis Pharmaceuticals.